Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 10—October 2009

CME ACTIVITY - Research

Community-Associated Methicillin-Resistant Staphylococcus aureus, Iowa, USA

MedscapeCME is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of MedscapeCME and Emerging Infectious Diseases. MedscapeCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MedscapeCME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at http://www.medscape.com/cme/eid; (4) view/print certificate.

Learning Objectives

• Upon completion of this activity, participants will be able to:

• Describe risk factors for healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infection

• Define multiresistant MRSA isolates

• Describe characteristics of patients who are likely to be infected by strains USA300/400 of MRSA

• Identify predictive factors for community-associated MRSA infection in 1 US state

• Describe recent patterns of community-associated MRSA infection in the United States

Editor

Beverly Merritt, Technical Writer-Editor, Emerging Infectious Diseases. Disclosure: Beverly Merritt has disclosed no relevant financial relationships.

CME AUTHOR

Désirée Lie, MD, MSEd, Clinical Professor, Family Medicine, University of California, Orange; Director, Division of Faculty Development, UCI Medical Center, Orange, California. Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.

AUTHORS

Philip Van De Griend, MPH; Loreen A. Herwaldt, MD; Bret Alvis, MD; Mary DeMartino, BS, MT, (ASCP)SM; Kristopher Heilmann, BS; and Diana DeSalvo Vonstein, BS, MPH, have disclosed no relevant financial relationships. Gary Doern, MD, has disclosed that he has served as an advisor or consultant to Astellas Pharma, Inc. and has served as a speaker or a member of a speaker's bureau for Pfizer Inc.; Cubist Pharmaceuticals; Schering-Plough Corporation; and Astellas Pharma, Inc. Patricia Winokur, MD, has disclosed that she has received grants for clinical research from CSL Limited and owns stock, stock options, or bonds from Johnson & Johnson Pharmaceutical Research & Development L.L.C. Daniel Diekema, MD, MS, has disclosed that he has received grants for clinical research from Merck & Co., Inc.; Pfizer Inc.; Schering-Plough Corporation; and Astellas Pharma, Inc.

Article Navigation

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

TOP